Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - vaccine
86
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
DESIGN OF UNIVERSAL H5 INFLUENZA VIRUS
VACCINE
CANDIDATES VIA ANTIGEN REORIENTATION
DESIGN OF UNIVERSAL H5 INFLUENZA VIRUS
VACCINE
CANDIDATES VIA ANTIGEN REORIENTATION Researchers at Stanford University have developed novel universal vaccine candidates for H5 influenza viruses. Influenza remains a serious threat to public health. H5 avian influenza strains are among the most concerning despite lack of documented human to human...
Published: 9/24/2024
|
Inventor(s):
Duo Xu
,
Peter Kim
Keywords(s):
Immunofocusing
,
Vaccine
Category(s):
Technology Classifications > Biology
HIGH THROUGHPUT METHOD FOR SCREENING LIPID NANOPARTICLE EFFICACY AND CYTOTOXICITY
HIGH THROUGHPUT METHOD FOR SCREENING LIPID NANOPARTICLE EFFICACY AND CYTOTOXICITY Researchers at Berkeley have developed synthetic cell membranes that are optimized for screening the toxicity and efficacy of lipid nanoparticle formulations in vitro, in a high throughput format. Lipid nanoparticles (LNPs) represent a highly effective and efficient...
Published: 4/22/2024
|
Inventor(s):
Markita Landry
,
Alison Lui
Keywords(s):
Nanoparticle
,
SARS-CoV-2
,
Vaccine
Category(s):
Technology Classifications > Biology
DESIGN OF A UNIVERSAL INFLUENZA
VACCINE
CANDIDATES VIA ANTIGEN REORIENTATION
DESIGN OF A UNIVERSAL INFLUENZA
VACCINE
CANDIDATES VIA ANTIGEN REORIENTATION Researchers at Stanford have developed a novel universal influenza vaccine candidate. Vaccines are a major feat of biomedical innovation. Successful vaccines produce broad humoral immunity to a pathogen to prevent subsequent infection. In this vein, adjuvants are compounds...
Published: 12/5/2023
|
Inventor(s):
Duo Xu
,
Peter Kim
Keywords(s):
Adjuvant
,
Alum
,
Infectious Disease
,
Vaccine
Category(s):
Technology Classifications > Biology
EF-Tu Targeting Antibody for Infection Treatment
Application Therapeutic monoclonal antibodies directed to Elongation Factor-Tu (EF-Tu) for the treatment of infections. Key Benefits An antibody that targets the protein EF-Tu, which is present on many types of bacteria involved in life-threatening infections. A research-grade antibody has been developed with animal data showing the ability to...
Published: 7/30/2024
|
Inventor(s):
Joanna Goldberg
,
Dina Moustafa
Keywords(s):
Microbiology/Infectious Diseases
,
Target
,
Vaccine
Category(s):
TechPub Algolia >
Vaccine
s
,
TechPub Algolia > Therapeutics
Generation of
Vaccine
s Preventing the Common Cold
Application A new class of
vaccine
s targeting the viruses causing the common cold, rhinoviruses (RV). Key Benefits Capsid-chimeric strains for developing new RV vaccines. Preclinical data with a prototype show the ability to induce a robust capsid-specific immune response. Straightforward and inexpensive vaccine manufacturing process utilizing...
Published: 7/30/2024
|
Inventor(s):
Sujin Lee
Keywords(s):
Chemistry
,
Microbiology/Infectious Diseases
,
Vaccine
Category(s):
TechPub Algolia >
Vaccine
s
IMMUNOGENIC EBOLAVIRUS FUSION PROTEINS AND RELATED METHODS
IMMUNOGENIC EBOLAVIRUS FUSION PROTEINS AND RELATED METHODS Researchers at Stanford have developed a novel
vaccine
strategy for ebolavirus using fusion proteins composed of the virus’ glycoprotein. Hemorrhagic fevers have become a major public health issue in Africa, the most notable of which being Ebola. Ebola has a notably high mortality...
Published: 10/6/2023
|
Inventor(s):
Peter Kim
,
Duo Xu
,
Abigail Powell
Keywords(s):
Ebola Virus
,
Infectious Disease
,
Vaccine
Category(s):
Technology Classifications > Biology
IMMUNOGENIC CORONAVIRUS FUSION PROTEINS AND RELATED METHODS
IMMUNOGENIC CORONAVIRUS FUSION PROTEINS AND RELATED METHODS Researchers at Stanford have developed fusion proteins as a novel
vaccine
strategy for SARS-CoV2. As the causative force of the COVID-19 pandemic, SARS-CoV2 caused massive sustained morbidity, mortality, and societal disruption worldwide. Though COVID-19 has largely transitioned from...
Published: 10/6/2023
|
Inventor(s):
Peter Kim
,
Natalia Friedland
,
Mrinmoy Sanyal
,
Payton Weidenbacher
Keywords(s):
Coronavirus
,
COVID
,
COVID-19
,
Infectious Disease
,
Vaccine
Category(s):
Technology Classifications > Biology
CHEMICALLY MODIFIED BACTERIAL PEPTIDOGLYCAN COMPOSITIONS AND USES THEREOF
CHEMICALLY MODIFIED BACTERIAL PEPTIDOGLYCAN COMPOSITIONS AND USES THEREOF Researchers at Stanford have developed a new microparticle
vaccine
scaffold for the development of immunogenic subunit vaccines. Vaccines are one of the most important biomedical advances of the 20th century. Protein vaccines, often referred to as subunit vaccines, have proved...
Published: 8/17/2023
|
Inventor(s):
Peter Kim
,
Carolyn Bertozzi
,
Frances RodrÃguez-Rivera
Keywords(s):
Adjuvant
,
Bacteria
,
Peptidoglycan
,
Vaccine
Category(s):
Technology Classifications > Biology
High Efficacy
Vaccine
and Microbicide Combination For Use Against HIV
Abstract: Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective antiretrovirals (ARVs). ARVs are effective at limiting replication and spread of the virus, and progression to acquired immuno-deficiency syndrome (AIDS). However, ARVs often lead to emergence of drug-resistant...
Published: 8/5/2024
|
Inventor(s):
Genoveffa Franchini
,
Marjorie Robert-Guroff
,
Daniel Appella
,
Sabrina Helmold Hait
,
Mohammed Rahman
,
Massimiliano Bissa
,
Ettore Appella
,
Lisa Marie Jenkins
,
Isabela Silva De Castro
Keywords(s):
Acquired Immuno-Deficiency Syndrome
,
ADCC
,
AIDS
,
Antibody-dependent Cellular Cytotoxicity
,
Efferocytosis
,
Envelope Glycoprotein 120
,
Envelope Variable Region
,
Franchini
,
gp120
,
HIV
,
Human Immunodeficiency Virus
,
Microbicide
,
SAMT-247
,
V1
,
Vaccine
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
TherapeuticArea > Infectious Disease
,
TherapeuticArea > Immunology
,
Application >
Vaccine
s
Single Domain Antibodies Targeting the S2 Subunit of SARS-CoV-2 Spike Protein
Abstract: The COVID-19 pandemic is a worldwide public health crisis with over 100 million confirmed cases and 2.4 million deaths as of February 2021. COVID-19 is caused by a novel coronavirus called SARS-CoV-2. Almost all the neutralizing antibodies targeting SARS-CoV-2 that are in development recognize the receptor binding domain (RBD) on the spike...
Published: 5/21/2024
|
Inventor(s):
Mitchell Ho
,
Zhijian Duan
,
Jesse Buffington
Keywords(s):
: COVID-19
,
ANTIBODY
,
Camel Nanobody
,
CORONAVIRUS
,
HO
,
Infectious Diseases
,
Nanobodies
,
Pandemic
,
SARS-CoV-2
,
Shark Nanobody
,
therapeutic
,
Vaccine
Category(s):
Collaboration Sought > Licensing
,
Collaboration Sought > Collaboration
,
Application > Therapeutics
,
TherapeuticArea > Immunology
,
TherapeuticArea > Infectious Disease
1
2
3
4
5
6
7
8
9